Clearmind Medicine

Company Overview

Snapshot

Founded in January 2021, Clearmind Medicine operates with 1–10 employees. The company has raised a total of $16.21M across six funding rounds. In November 2022, Clearmind Medicine uplisted to the Nasdaq Capital Market.

Business overview

Clearmind Medicine is a Health Tech & Life Sciences company focused on developing treatments for binge behavior and mental health conditions, including alcohol use disorder, binge eating, and depression. Its core technology involves MEAI, a psychedelic-derived compound designed to provide a euphoric, alcohol-like experience while reducing the desire for alcohol consumption. The company operates within the Drugs Discovery & Development sector, targeting healthcare and laboratory markets with its novel therapeutic solutions.

Strategic signal

In October 2025, Clearmind Medicine announced the completion of the first cohort treatment in its FDA-approved Phase I/IIa clinical trial for Alcohol Use Disorder. This milestone indicates significant progress in the clinical development of its lead compound, CMND-100, and provides a positive signal to investors regarding the company's advancement towards commercialization and addressing a critical public health issue.

Company Intelligence Q&A

What was a significant recent development for Clearmind Medicine's clinical trials?

In October 2025, Clearmind Medicine completed the first cohort treatment in its FDA-approved Phase I/IIa clinical trial for Alcohol Use Disorder, marking a key advancement in its therapeutic development.

What is Clearmind Medicine's strategy for intellectual property protection?

In September 2024, Clearmind Medicine announced the publication of an international patent application for an innovative MDMA-based combination treatment, demonstrating its focus on expanding its intellectual property portfolio for psychedelic-derived therapies.

What was a recent strategic partnership for Clearmind Medicine?

In September 2023, Clearmind Medicine announced a clinical research collaboration with Johns Hopkins University to evaluate CMND-100 in patients with Alcohol Use Disorder, indicating a strategic move to partner with leading academic institutions for clinical validation.

What was Clearmind Medicine's recent activity regarding its stock listing?

In November 2022, Clearmind Medicine announced the closing of a US$7.5 million public offering and uplisted to the Nasdaq Capital Market, signifying a major step in its public market presence.

What was a recent financial event for Clearmind Medicine?

In September 2023, Clearmind Medicine closed a US$2.25 million public offering, as Aegis Capital Corp. acted as exclusive placement agent for the transaction.